

**EARLY WARNING REPORT  
FILED PURSUANT TO NATIONAL INSTRUMENT 62-103**

**Item 1 – Security and Reporting Issuer**

*1.1 State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities.*

Common shares of InnoCan Pharma Corporation (the “**Issuer**”), head office located at 1015, 926 - 5 Avenue SW Calgary, Alberta T2P 0N7.

*1.2 State the name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place.*

This report is filed in respect of the acquisition of common shares and common share purchase warrants of the Issuer in connection with a share exchange transaction pursuant to which the Issuer acquired 100% of the outstanding securities of InnoCan Pharma Ltd. which was completed on September 25, 2019 (the “**Transaction**”).

**Item 2 – Identity of the Acquiror**

*2.1 State the name and address of the acquiror.*

The acquiror is Tamar Innovest Limited (formerly Solsken Limited) (“**Tamar**”), head office located at 3 Bedlam Court, Office Suite 3 Montarik Building, Gibraltar GX11 1AA.

*2.2 State the date of the transaction or other occurrence that triggered the requirement to file this report and briefly describe the transaction or other occurrence.*

On September 25, 2019, Tamar acquired an aggregate of 26,496,817 common shares of the Issuer and 15,981,916 common share purchase warrants of the Issuer pursuant to the Transaction.

*2.3 State the names of any joint actors.*

Not applicable.

**Item 3 – Interest in Securities of the Reporting Issuer**

*3.1 State the designation and number or principal amount of securities acquired or disposed of that triggered the requirement to file this report and the change in the acquiror’s securityholding percentage in the class of securities.*

Tamar acquired ownership and control of 26,496,817 common shares in the capital of the Issuer. The acquisition of the common shares represents approximately 18.4% of the Issuer’s current issued and outstanding common shares. Tamar also acquired ownership and control of 15,981,916 common share purchase warrants. The acquisition of the common share purchase warrants represents approximately 81.3% of the Issuer’s current issued and outstanding common share purchase warrants.

*3.2 State whether the acquiror acquired or disposed ownership of, or acquired or ceased to have control over, the securities that triggered the requirement to file this report.*

Tamar acquired ownership and control of the securities that are the subject of this report.

*3.3 If the transaction involved a securities lending arrangement, state that fact.*

Not applicable.

*3.4 State the designation and number or principal amount of securities and the acquiror's securityholding percentage in the class of securities, immediately before and after the transaction or other occurrence that triggered the requirement to file this report.*

Prior to completion of the Transaction, Tamar held 4,000,000 common shares of the Issuer and nil common share purchase warrants. Following completion of the Transaction, Tamar has ownership and control of 30,496,817 common shares of the Issuer, representing approximately 21.2% of the issued and outstanding common shares of the Issuer, and 15,981,916 common share purchase warrants of the Issuer, representing approximately 81.3% of the Issuer's current issued and outstanding common share purchase warrants.

*3.5 State the designation and number or principal amount of securities and the acquiror's securityholding percentage in the class of securities referred to in Item 3.4 over which*

*(a) the acquiror, either alone or together with any joint actors, has ownership and control,*

Tamar has ownership and control over 30,496,817 common shares of the Issuer, representing approximately 21.2% of the issued and outstanding common shares of the Issuer, and 15,981,916 common share purchase warrants of the Issuer, representing approximately 81.3% of the Issuer's current issued and outstanding common share purchase warrants.

*(b) the acquiror, either alone or together with any joint actors, has ownership but control is held by persons or companies other than the acquiror or any joint actor, and*

Not applicable.

*(c) the acquiror, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.*

Not applicable.

*3.6 If the acquiror or any of its joint actors has an interest in, or right or obligation associated with, a related financial instrument involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the related financial instrument and its impact on the acquiror's securityholdings.*

Not applicable.

*3.7 If the acquiror or any of its joint actors is a party to a securities lending arrangement involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the arrangement including the duration of the arrangement, the number or principal*

*amount of securities involved and any right to recall the securities or identical securities that have been transferred or lent under the arrangement.*

Not applicable.

*3.8 If the acquiror or any of its joint actors is a party to an agreement, arrangement or understanding that has the effect of altering, directly or indirectly, the acquiror's economic exposure to the security of the class of securities to which this report relates, describe the material terms of the agreement, arrangement or understanding.*

Not applicable.

#### **Item 4 – Consideration Paid**

*4.1 State the value, in Canadian dollars, of any consideration paid or received per security and in total.*

The common shares and the common share purchase warrants of the Issuer were acquired in exchange for Tamar's securities in InnoCan Pharma Ltd., being 28,840 ordinary shares of InnoCan Pharma Ltd., an aggregate of 21,744 common share purchase warrants of InnoCan Pharma Ltd. and an unsecured convertible note in the principal amount of USD\$500,000 (which converted into 5,299,419 common shares of the Issuer upon completion of the Transaction), pursuant to the Transaction.

*4.2 In the case of a transaction or other occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, disclose the nature and value, in Canadian dollars, of the consideration paid or received by the acquiror.*

See the response to Item 4.1.

*4.3 If the securities were acquired or disposed of other than by purchase or sale, describe the method of acquisition or disposition.*

See the response to Item 4.1.

#### **Item 5 – Purpose of the Transaction**

*State the purpose or purposes of the acquiror and any joint actors for the acquisition or disposition of securities of the reporting issuer. Describe any plans or future intentions which the acquiror and any joint actors may have which relate to or would result in any of the following: (a) the acquisition of additional securities of the reporting issuer, or the disposition of securities of the reporting issuer; (b) a corporate transaction, such as a merger, reorganization or liquidation, involving the reporting issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of the assets of the reporting issuer or any of its subsidiaries; (d) a change in the board of directors or management of the reporting issuer, including any plans or intentions to change the number or term of directors or to fill any existing vacancy on the board; (e) a material change in the present capitalization or dividend policy of the reporting issuer; (f) a material change in the reporting issuer's business or corporate structure; (g) a change in the reporting issuer's charter, bylaws or similar instruments or another action which might impede the acquisition of control of the reporting issuer by any person or company; (h) a class of securities of the reporting issuer being delisted from, or ceasing to be authorized to be quoted on, a marketplace; (i) the issuer ceasing to be a reporting issuer in any jurisdiction of Canada; (j) a solicitation of proxies from securityholders; (k) an action similar to any of those enumerated above.*

The securities were acquired in connection with the Transaction, and for investment purposes. Tamar has no present intentions to acquire additional securities of the Issuer, except in connection with the possible exercise of common share purchase warrants of the Issuer held by Tamar. Additionally, Tamar may in the future acquire or dispose of securities of the Issuer as circumstances or market conditions may warrant.

**Item 6 – Agreements, Arrangements, Commitments or Understandings With Respect to Securities of the Reporting Issuer**

*Describe the material terms of any agreements, arrangements, commitments or understandings between the acquiror and a joint actor and among those persons and any person with respect to securities of the class of securities to which this report relates, including but not limited to the transfer or the voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Include such information for any of the securities that are pledged or otherwise subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities, except that disclosure of standard default and similar provisions contained in loan agreements need not be included.*

Not applicable.

**Item 7 – Change in Material Fact**

*If applicable, describe any change in a material fact set out in a previous report filed by the acquiror under the early warning requirements or Part 4 in respect of the reporting issuer's securities.*

Not applicable.

**Item 8 – Exemption**

*If the acquiror relies on an exemption from requirements in securities legislation applicable to formal bids for the transaction, state the exemption being relied on and describe the facts supporting that reliance.*

Not applicable.

**Item 9 – Certification**

I, as the acquiror, certify, or I, as the agent filing the report on behalf of an acquiror, certify to the best of my knowledge, information and belief, that the statements made in this report are true and complete in every respect.

**Dated** as of the 4<sup>th</sup> day of March, 2021.

**TAMAR INNOVEST LIMITED.**

Per: /signed/ "Ralph Bossino"  
Ralph Bossino  
Director